Remove 2023 Remove Compounding Remove Labelling
article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 This is projected to grow at the highest compound annual growth rate of 5.27

Packaging 118
article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more

STAT

 One person also experienced hypoglycemia in 2023 after injecting a compounded version of Ozempic, said the organization, which represents 55 regional poison centers across the country and works with the U.S. Ozempic and similar diabetes medicines have been increasingly used off label for weight loss.

article thumbnail

Wegovy backorder: Why it happens and what to do about it

The Checkup by Singlecare

Others have just waited or turned to a compounded version of the drug,” Dr. Jordan says. Because those drugs are not FDA approved for weight loss, like Wegovy, healthcare providers may prescribe them off-label. When medications are prescribed off-label, there is a small chance that the patient’s insurance covers the medication.

article thumbnail

FDA accepts Outlook Therapeutics’ BLA for wet AMD treatment

Pharmaceutical Technology

On receiving approval, the treatment is expected to replace the requirement to use unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for wet AMD treatment. The regulator has set 29 August 2023 as a Prescription Drug User Fee Act (PDUFA) goal date.

FDA 59
article thumbnail

Electronic smart packaging market to value nearly $3b in 2033

European Pharmaceutical Review

This represents a compound annual growth rate (CAGR) of 15.4 percent from 2023, according to the data. This is driving the adoption of item-level smart labelling , the report noted. A market report has identified that global demand for electronic smart packaging will reach $2.6 billion in 2033.

article thumbnail

FDA guidance highlights E&L considerations for ophthalmic drug products

European Pharmaceutical Review

Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. This document is revised from a version published in October 2023.

FDA 98